HIV/AIDS Topics CROI 2017: How Does Vedolizumab Antibody Therapy Lead to Sustained Viral Remission?
- Details
- Category: Search for a Cure
- Published on Thursday, 16 March 2017 00:00
- Written by Liz Highleyman
HIV and its monkey cousin SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope, which helps the virus enter gut cells during early infection, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. This finding may help explain how an antibody against alpha-4 beta-7 produced sustained viral remission in monkeys.
CROI 2017: Dolutegravir Monotherapy Fails to Maintain Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 08 March 2017 00:00
- Written by Liz Highleyman
Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard 3-drug combination regimen, according to research presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. But evidence continues to show that dolutegravir plus a single other drug can work well as maintenance therapy.
CROI 2017: Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV
- Details
- Category: Search for a Cure
- Published on Tuesday, 28 February 2017 00:00
- Written by Liz Highleyman
Participants at a Community HIV Cure Research Workshop on February 12, in advance of the Conference on Retroviruses and Opportunistic Infections in Seattle, held a "birthday" party for Timothy Ray Brown -- formerly known as the Berlin Patient -- to celebrate 10 years since the bone marrow transplant that would lead to the only known cure for HIV.
CROI 2017: Integrase Inhibitors May Increase Risk of IRIS in Late Presenters for HIV Treatment
- Details
- Category: HIV Treatment
- Published on Wednesday, 08 March 2017 00:00
- Written by Keith Alcorn
HIV integrase inhibitors such as dolutegravir and raltegravir may increase the risk of immune reconstitution inflammatory syndrome or IRIS, according to studies from the Netherlands and France presented last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.
CROI 2017: Bone Marrow Transplant Patient Off ART for 288 Days Without HIV Rebound
- Details
- Category: Search for a Cure
- Published on Tuesday, 28 February 2017 00:00
- Written by Liz Highleyman
A HIV-positive bone marrow transplant recipient at the Mayo Clinic experienced prolonged viral remission lasting nearly 10 months -- longer than the so-called Boston patients -- after interrupting antiretroviral therapy (ART), according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle. Although his viral load eventually rebounded, his HIV reservoirs appeared to be reduced.
CROI 2017: Several New Candidates in HIV Drug Pipeline Discussed at Conference
- Details
- Category: Experimental HIV Drugs
- Published on Saturday, 04 March 2017 00:00
- Written by Liz Highleyman
This year's Conference on Retroviruses and Opportunistic Infections (CROI), held last month in Seattle, included presentations on several new investigational antiretroviral drugs in development, reflecting a more robust pipeline than we have seen in recent years.
CROI 2017: Time with Transmissible HIV Viral Load Has Fallen By Three-Quarters Since 2000
- Details
- Category: HIV Treatment
- Published on Tuesday, 28 February 2017 00:00
- Written by Gus Cairns
A study by the Centers for Disease Control and Prevention (CDC) presented at the recent Conference on Retroviruses and Opportunistic Infections in Seattle found that the proportion of time people with HIV in the U.S. spend in care but not virally suppressed has fallen from 40% to 10% in the last 15 years. The study also found that young people, black people, and people with public rather than private health coverage spent less time with viral load below 1500 copies/mL, the World Health Organization (WHO) threshold for HIV transmission.
More Articles...
- CROI 2017: Treatment-as-Prevention Study Sees Substantial Drug Resistance, but No Impact on HIV Therapy
- CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies
- CROI 2017: Monoclonal Antibodies Show Promise for HIV+ People with Few Treatment Options
- CROI 2017: New NNRTI Doravirine Shows Good Efficacy in Phase 3 Study
- CROI 2017: Spanish HIV Vaccine Induces Control Off ART in Nearly 40% of Recipients
Web Design and Development by